|
Title
|
Published
|
Price
|
|
Marketing and Sales Guide to the Danish Biotech Market 2003
By: BioSeeker Group AB
Executive Summary
It is now possible for you to decide whether the Danish biotech industry, or any of its individual segments, is of potential value for your business purposes. This report provides you
|
more...
|
5/16/2003
|
$1,680.75
|
|
Molecular Approaches Towards HCV Therapy - The Complete Guide
By: BioSeeker Group AB
Executive Summary
There is still a strong interest in developing novel therapies for HCV despite the promise of the pegylated interferons. The enthusiasm for specifically targeted HCV drugs such as protease inhibitors is
|
more...
|
4/12/2003
|
$2,700.00
|
|
Market and Sales Guide to the Swedish Biotech Market 2003
By: BioSeeker Group AB
This is the first and only market and sales guide to the whole biotech industry in Sweden. It is now possible for you to decide whether the Swedish biotech industry or any segment of it
|
more...
Buy by the section | Search inside this report
|
2/5/2003
|
$2,018.25
|
|
New Targets and Drug Discovery Platforms in Antifungal R&D
By: BioSeeker Group AB
Executive Summary
According to the Antifungal Work Group at NIH there is a “critical need for the development of antifungal agents“. The urgency stems from the therapeutic limitations of the present antifungal compounds
|
more...
|
11/25/2002
|
$1,005.75
|
|
Future HCV Drug Discovery Technologies
By: BioSeeker Group AB
Executive Summary
The main hindrance to drug development for hepatitis C has been the lack of a small animal model or productive tissue culture system for assessing drug action. This problem has been
|
more...
|
11/25/2002
|
$735.75
|
|
Ion Channel Assays as Therapeutic Targets for Multiple Diseases
By: BioSeeker Group AB
Ion channels play an important role in numerous cell types and occur as large families of related genes with cell-specific expression patterns. Considering the publication of the human genome and the progress in transcription profiling
|
more...
Search inside this report
|
11/7/2002
|
$857.25
|
|
Ion Channels as Therapeutic Targets for Multiple Diseases
By: BioSeeker Group AB
Executive Summary
Ion channels play an important role in numerous cell types and occur as large families of related genes with cell-specific expression patterns. Considering the publication of the human genome and the
|
more...
|
11/7/2002
|
$924.75
|
|
Fierce Competition for a Shrinking HCV Market
By: BioSeeker Group AB
Hepatitis C virus (HCV) has already caused a global epidemic, but the worst may yet be to come. According to the CDC nearly 4 million people are or have been infected with HCV in the
|
more...
Buy by the section | Search inside this report
|
10/21/2002
|
$911.25
|
|
The Next Generation of Antifungals: Triazoles vs. Peptides
By: BioSeeker Group AB
According to the Antifungal Work Group at NIH there is a "critical need for the development of antifungal agents" (Draft report of the Antifungal Working Group). "There is not a single rapidly fungicidal, non-toxic drug
|
more...
Search inside this report
|
10/8/2002
|
$668.25
|
|
Swedish Biopharma Profiles 2002
By: BioSeeker Group AB
The Swedish biopharma industry has experienced a dramatic growth from 25 companies in 1996 to 52 companies in 2002. In this informative profile report, BioSeeker Groups presents all 52 biopharma companies with either research and
|
more...
|
9/25/2002
|
$471.15
|
|
R&D in Swedish Biopharma Companies 2002
By: BioSeeker Group AB
The Swedish biopharma industry is founded on a very strong scientific base. This is reflected in the technology platforms that are readily identified among many of the companies. This report focuses on the R&D performed
|
more...
|
9/25/2002
|
$492.75
|
|
Swedish Biopharma Industry - The Next Wave
By: BioSeeker Group AB
Sweden is one of the world’s most densely populated countries when it comes to the number of biotechs. Despite having less than 9 million inhabitants, Sweden has more than 380 biotech companies. In the report,
|
more...
Search inside this report
|
9/17/2002
|
$1,147.50
|
|
Ion Channel Assays in the Drug Discovery Process
By: BioSeeker Group AB
This report from BioSeeker Group AB identifies 22 companies with a strong focus within the emerging field of ion channel assay technology. "Ion Channel Assays in the Drug Discovery Process" is compiles and assesses the
|
more...
Search inside this report
|
6/3/2002
|
$3,408.75
|
|
The Competitive Landscape of Cancer Gene Therapy (2nd issue)
By: BioSeeker Group AB
Cancer is not one single disease but can be divided into almost 200 different diseases. In the United States, overall annual costs associated with cancer currently amount to $107 billion and the worldwide anti-cancer market,
|
more...
Buy by the section | Search inside this report
|
5/13/2002
|
$3,071.25
|
|
Commercializing on Tumor Antigens: Analytical Perspectives
By: BioSeeker Group AB
A new report from BioSeeker Group is available to provide you with in-depth
coverage, candid information and analysis of the tumor antigen field. This
report presents an up-to-date "de novo" approach and is a significant
|
more...
Buy by the section | Search inside this report
|
2/1/2002
|
$5,062.50
|
|
Pan-European Investors in Biotechnology
By: BioSeeker Group AB
This report brings you up to date with 526 pan European investors in biotechnology. We list their financial strength and how they prefer to invest. Target key VC principals for each firm via or detailed
|
more...
Search inside this report
|
2/1/2002
|
$538.65
|
|
Emerging Cancer Therapeutics
By: BioSeeker Group AB
Cancer is not one single disease but can be divided into almost 200 different diseases. In the United States, overall annual costs associated with cancer currently amount to $107 billion and the worldwide anti-cancer market,
|
more...
Search inside this report
|
1/1/2002
|
$4,029.75
|
|
Cancer Immunotherapy beyond Monoclonals
By: BioSeeker Group AB
Cancer is not one single disease but can be divided into almost 200 different diseases. In the United States, overall annual costs associated with cancer currently amount to $107 billion and the worldwide anti-cancer market,
|
more...
Buy by the section | Search inside this report
|
9/1/2001
|
$2,261.25
|
|
Title
|
Published
|
Price
|